FMR1 and fragile X syndrome: However, a subsequent international, multicenter, double-blind, randomized, controlled Phase III clinical trial in children and adolescents with FXS did not achieve statistical significance for the primary endpoint in the full cohort but showed significant improvements in patients with >90% FMR1 methylation [156].